Adicet Bio, Inc. (ACET)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 1
Do Nothing: ACET is in a broken downtrend printing a new 52-week low (2.78 vs SMA50 5.93, RSI 17.5, ADX 67 down) and is blocked on four independent hard gates — fundamentalScore 1 < 3, qualitativeScore 1 < 3, avgDollarVolume20 $814,401 < $5,000,000, and recent 3-session dollar volume $983,021 < $1,500,000; no pullback limit qualifies (price below SMA50 with MACD < 0 is a countertrend bid) and no breakout stop qualifies (trigger 2.98 gives risk 0.32 = 0.94xATR, under the 1.0xATR floor at a 12.2% ATR reading).
Company overview
Adicet Bio, Inc. is a biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It engineers gamma delta T cells with chimeric antigen receptors and T cell receptor-like antibodies to enhance immune response and target tumors. The company's lead candidate, ADI-001, is in Phase I trials for non-Hodgkin's lymphoma, with ADI-002 in preclinical stages for solid tumors.
Fundamental
very weakAdicet Bio's fundamentals are speculative, with a going-concern warning and a need for financing at depressed valuations.
Pre-revenue clinical-stage biotech carrying an explicit going-concern qualification, a $100.9M but shrinking cash pile, and a ~$26M market capitalization that values the equity at roughly a quarter of its cash. Encouraging early lupus data and a debt-free balance sheet are real, but the company must finance a pivotal program at a deeply depressed share price before any revenue exists — the fundamentals read as speculative and unsuitable as an actionable short-horizon investment.
Sentiment
very weakSentiment is weak, with no near-term catalysts and a flat media response.
Dominant near-term items are the 2026-11-05 Q3 print (announced) — an $0.18 EPS miss and $18.9M net loss partly offset by lower operating costs — and the 2026-11-06 Guggenheim Buy reiteration with the target cut to $55 from $90, sitting on an unresolved, undated prula-cel pivotal lupus-nephritis program (announced, date TBD); the 14-day scoring tape is flat (3 scored items, polarity ≈ +0.03) and the sentiment delta is indeterminate because the baseline holds only one scored item (+0.60). Severe red-flag cap applied: the Q3 2026 10-Q filed 2026-11-05 carries an explicit substantial-doubt going-concern conclusion, which dominates the constructive clinical narrative.
Technical
very weakThe stock is in a deep downtrend, hitting new lows with no signs of reversal.
ACET is in a confirmed primary downtrend with no bullish structure to trade. At 2.78 the stock sits 21% below its SMA20 (3.53), 53% below its SMA50 (5.93) and 63% below its SMA200 (7.43), and the 2026-11-13 session printed a fresh 52-week low of 2.73 (equal to the yearLow). RSI14 17.54 and Williams %R -95.97 are deeply oversold but show no basing or positive divergence, while ADX14 67.39 marks a very strong directional trend that is downward given the price/MA stack. MACD remains deeply negative (line -0.83 vs signal -0.92) with only a marginal histogram improvement (+0.09). Score 1 (bearish/broken structure).
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

